Paul Tudor Jones sees potential market rally after late October
Investing.com - Mizuho has reiterated an Outperform rating and $32.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside from the current price of $11.62. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $28 to $55.
Corbus Pharmaceuticals received the Fast Track Designation for CRB-701, its Nectin-4-targeting antibody drug conjugate for treating recurrent or metastatic head and neck squamous cell carcinoma in patients previously treated with platinum-based chemotherapy and anti-PD(L)-1 therapy.
Mizuho views this development as a net positive for Corbus, noting that Fast Track status potentially allows for accelerated development timelines and provides external validation for CRB-701 and its market opportunity.
The research firm emphasized that while many investors are focused on CRB-913, the company’s CB1-based asset for obesity, CRB-701 represents Mizuho’s primary valuation driver for Corbus and the basis for its enthusiasm about the company.
Mizuho’s analysis comes ahead of the first Phase 1/2 dose optimization data for CRB-701, which Corbus plans to present at the ESMO conference next month.
In other recent news, Corbus Pharmaceuticals Holdings Inc. has announced that updated clinical data from its Phase 1/2 study of CRB-701 will be presented at the European Society for Medical Oncology Congress in October 2025. This presentation will focus on the ongoing trial of CRB-701, a Nectin-4-targeting antibody-drug conjugate, in patients with both urothelial and non-urothelial solid tumors. The abstract detailing this study has been accepted for presentation at the congress, highlighting the company’s progress in cancer treatment research. Additionally, Corbus Pharmaceuticals has commenced the multiple ascending dose portion of its Phase 1 trial for CRB-913, aimed at treating obesity. This follows the completion of the single ascending dose portion earlier this year, with no treatment-related neuropsychiatric events reported thus far. These developments mark significant steps in Corbus Pharmaceuticals’ ongoing research efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.